{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002800","form_type":"8-K","ticker":"OSUR","cik":"0001116463","company_name":"ORASURE TECHNOLOGIES INC","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.911262+00:00","generated_at":"2026-06-19T13:08:19.834224+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce","bullets":["Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).","GAAP EPS $0.21, non-GAAP EPS $0.36; full-year GAAP EPS ($0.25), non-GAAP $0.34.","Restructuring combines Molecular & Diagnostics units; 11% non-production role cuts, $15M annual savings by June 2023.","Cash $110.8M, up $9M QoQ; guides Q1 revenue $125–130M (85–92% YoY growth).","New federal InteliSwab contracts through Nov 2023; deal with Quest for saliva collection kits."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002800","json":"https://secwatch.observer/filing/0000950170-23-002800.json","markdown":"https://secwatch.observer/filing/0000950170-23-002800.md","text":"https://secwatch.observer/filing/0000950170-23-002800.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/0000950170-23-002800-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/osur-20230214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T13:08:19.834224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a3eee0dd388f4b0ceeff63b6c819b57ffa43805d","claim":"ORASURE TECHNOLOGIES INC reported Q4 2022 results: revenue $123,078, net income 15,561, EPS $0.21.","evidence_excerpt":"Financial Highlights Three Months Ended Year Ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Core Diagnostics $ 18,400 $ 17,898 3 % $ 70,007 $ 67,333 4 % InteliSwab 88,857 14,770 502 233,666 22,707 929 Total Diagnostics 107,257 32,668 228 303,673 90,040 237 Core Molecular Solutions 15,684 22,936 (32 ) 74,147 89,467 (17 ) COVID-19 kits 137 7,964 (98 ) 9,659 54,167 (82 ) Total Molecular Solutions 15,821 30,900 (49 ) 83,806 143,634 (42 ) Total Revenue $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Three Months Ended Year ended December 31, December 31, 2022 2021 % Change 2022 2021 % Change Net revenues $ 123,078 $ 63,568 94 % $ 387,479 $ 233,674 66 % Gross profit 49,589 27,133 83 147,637 117,600 26 Gross margin 40 % 43 % 38 % 50 % Non-GAAP gross profit 50,126 28,685 75 154,464 121,708 27 Non-GAAP gross margin 41 % 45 % 40 % 52 % Operating income (loss) 13,435 (9,371 ) NM (22,957 ) (10,164 ) NM Operating margin 11 % -15 % -6 % -4 % Non-GAAP operating income (loss) 1","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/0000950170-23-002800-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Q4 2022"},{"label":"Revenue","value":"$123,078"},{"label":"Net income","value":"15,561"},{"label":"EPS","value":"$0.21"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}